【摘要】 免疫治疗正在重塑可切除胃癌的治疗格局。围术期化疗已成为标准治疗之一,但病理完全缓解率仍较低。MATTERHORN试验显示了病理反应和无事件生存期的显著改善。本文总结了围术期免疫检查点抑制剂的治疗现状,未来朝向以生物标志物为驱动的个体化多模式治疗胃癌的方向发展。更多还原

【Abstract】 Immunotherapy is reshaping the treatment landscape for resectable gastric cancer. Perioperative chemotherapy has become one of the standard treatment options, yet the rate of pathological complete response remains low. The MATTERHORN trial demonstrated significant improvements in pathological response and event-free survival(EFS). This article summarizes the current status of perioperative immune checkpoint inhibitors(ICIs) therapy and highlights its future direction toward biomarker-driven, individualized multimodal treatment for gastric cancer.更多还原